The role of Toll-like receptor 4 (TLR4) in cardiac ischaemic-reperfusion injury, cardioprotection and preconditioning

被引:32
作者
Lee, Sam Man [1 ]
Hutchinson, Mark [1 ,2 ]
Saint, David A. [1 ]
机构
[1] Univ Adelaide, Sch Med, Adelaide, SA, Australia
[2] Univ Adelaide, Ctr Nanoscale Biophoton, Adelaide, SA, Australia
关键词
cardiac ischemia-reperfusion injury; cardioprotection; innate immune system; ischemia reperfusion injury; preconditioning; toll-like receptor; TLR4; BOX; 1; PROTEIN; REDUCES INFARCT SIZE; MOBILITY GROUP BOX-1; MYOCARDIAL-ISCHEMIA; ISCHEMIA/REPERFUSION INJURY; INFLAMMATORY RESPONSE; GLOBAL-ISCHEMIA; CUTTING EDGE; KAPPA-B; PROTECTION;
D O I
10.1111/1440-1681.12602
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cardiac ischaemic-reperfusion injury (IRI) remains the primary cause of mortality throughout the developed world. Molecular mechanisms underlying IRI are complex and are often interlinked with each other driving a synergistic response. Toll-like receptor 4 (TLR4), an immunosurveillance receptor, is known to enhance tissue injury during IRI by enhancing the inflammatory response. The release of endogenous components during IRI bind onto TLR4 leading to the activation of multiple signalling kinases. Once this event occurs these proteins are defined as danger associated molecular patterns molecules (DAMPs) or alarmins. Examples include heat shock proteins, high mobility group box one (HMGB1) and extracellular matrix proteins, all of which are involved in IRI. However, literature in the last two decades suggests that transient stimulation of TLR4 may suppress IRI and thus improve cardiac recovery. Furthermore, it remains to be seen what role TLR4 plays during ischaemic-preconditioning where acute bouts of ischaemia, preceding a harmful bout of ischaemic-reperfusion, is cardioprotective. The other question which also needs to be considered is that if transient TLR4 signalling drives a preconditioning response then what are the ligands which drive this? Hence the second part of this review explores the possible TLR4 ligands which may promote cardioprotection against IRI.
引用
收藏
页码:864 / 871
页数:8
相关论文
共 83 条
[1]  
Aksöyek S, 2002, SHOCK, V18, P476
[2]   High-mobility group box-1 in ischemia-reperfusion injury of the heart [J].
Andrassy, Martin ;
Volz, Hans C. ;
Igwe, John C. ;
Funke, Benjamin ;
Eichberger, Sebastian N. ;
Kaya, Ziya ;
Buss, Sebastian ;
Autschbach, Frank ;
Pleger, Sven T. ;
Lukic, Ivan K. ;
Bea, Florian ;
Hardt, Stefan E. ;
Humpert, Per M. ;
Bianchi, Marco E. ;
Mairbaeurl, Heimo ;
Nawroth, Peter P. ;
Remppis, Andrew ;
Katus, Hugo A. ;
Bierhaus, Angelika .
CIRCULATION, 2008, 117 (25) :3216-3226
[3]   Tumor necrosis factor receptor-associated factors (TRAFs) - a family of adaptor proteins that regulates life and death [J].
Arch, RH ;
Gedrich, RW ;
Thompson, CB .
GENES & DEVELOPMENT, 1998, 12 (18) :2821-2830
[4]   Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart - p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion [J].
Bogoyevitch, MA ;
GillespieBrown, J ;
Ketterman, AJ ;
Fuller, SJ ;
BenLevy, R ;
Ashworth, A ;
Marshall, CJ ;
Sugden, PH .
CIRCULATION RESEARCH, 1996, 79 (02) :162-173
[5]   Kidney ischemic preconditioning [J].
Bonventre, JV .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2002, 11 (01) :43-48
[6]   ENDOTOXIN PRETREATMENT INCREASES ENDOGENOUS MYOCARDIAL CATALASE ACTIVITY AND DECREASES ISCHEMIA REPERFUSION INJURY OF ISOLATED RAT HEARTS [J].
BROWN, JM ;
GROSSO, MA ;
TERADA, LS ;
WHITMAN, GJR ;
BANERJEE, A ;
WHITE, CW ;
HARKEN, AH ;
REPINE, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (07) :2516-2520
[7]   Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart [J].
Chong, AJ ;
Shimamoto, A ;
Hampton, CR ;
Takayama, H ;
Spring, DJ ;
Rothnie, CL ;
Yada, M ;
Pohlman, TH ;
Verrier, ED .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 128 (02) :170-179
[8]   Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].
Chung, ES ;
Packer, M ;
Lo, KH ;
Fasanmade, AA ;
Willerson, JT .
CIRCULATION, 2003, 107 (25) :3133-3140
[9]   Protective effects of ischemic preconditioning for liver resection performed under inflow occlusion in humans [J].
Clavien, PA ;
Yadav, S ;
Sindram, D ;
Bentley, RC .
ANNALS OF SURGERY, 2000, 232 (02) :155-162
[10]   PRECONDITIONING CAUSES IMPROVED WALL MOTION AS WELL AS SMALLER INFARCTS AFTER TRANSIENT CORONARY-OCCLUSION IN RABBITS [J].
COHEN, MV ;
LIU, GS ;
DOWNEY, JM .
CIRCULATION, 1991, 84 (01) :341-349